
Opinion|Videos|February 20, 2025
Reflections and Future Directions in R/R ALL
Panelists discuss collaboration strategies for chimeric antigen receptor (CAR) T-cell therapy referral, reflections on advancements in relapsed/refractory acute lymphoblastic leukemia (R/R ALL) throughout 2024, key accomplishments, and future opportunities for progress in 2025.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Dr. O’Dwyer to Dr. Logan: How do you partner or collaborate with your affiliated sites and/or community colleagues to ensure patients are being referred to CAR T-cell therapy?
Closing
- Dr. O’Dwyer: Before we wrap up, I’d like to hear your final thoughts and reflections on the strides we made throughout 2024—including new/exciting data presented at ASH 2024. Let’s consider what opportunities/what we are looking forward to ahead in 2025.
- What accomplishments in R/R ALL are you most proud of? Which developments stand out as pivotal in shaping clinical practice?
- What are you most excited about in 2025? What areas are primed for significant progress? What do you hope to achieve in the coming year?
Advertisement
Related to this article

Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.

The FDA gave a CRL to the NDA seeking the approval of Orviglance for use in the detection of liver metastases in patients with severe kidney impairment.

The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.

In a Roswell Park study, changes focused on standardization of care and donor selection, contributing to a 1-year overall survival rate of 92.6%.

Savolitinib received conditional NMPA approval in China for MET-amplified gastric or GEJ adenocarcinoma after prior systemic therapy, based on a 32.3% ORR.

Ropeginterferon alfa-2b has been approved by Health Canada for the treatment of adult patients with polycythemia vera.

Divarasib demonstrated superior PFS and OS versus sotorasib or adagrasib in the phase III Krascendo 1 trial in previously treated KRAS G12C–mutant NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus Lenalidomide/Rituximab Win EU Approval for R/R Follicular Lymphoma
2
TP53 Status and Time Toxicity Shape Sequencing Decisions in EGFR-Mutated NSCLC
3
Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 NSCLC Trial
4
Savolitinib Gains NMPA Approval for MET-Amplified Gastric and GEJ Adenocarcinoma
5

